1. An emulsion concentrate comprising:
(a) 3 to 5% by weight lauryl glucoside,
(b) 1 to 2% by weight myristyl glucoside,
(c) 5 to 7% by weight polyglycerol-2-dipolyhydroxystearate,
(d) 4 to 8% by weight of a C12-24 fatty alcohol,
(e) 70 to 75% by weight of an oil component,
(f) 4 to 5% by weight of a hydrotrope selected from the group consisting of a diol, a polyol and a glycerol, and mixtures thereof; and
(g) 2 to 10% by weight water.
2. The emulsion concentrate of claim 1, wherein the emulsion has a viscosity at 23\xb0 C. of less than 2,000 mPa.s, as measured with a Brookfield RVF viscosimeter, spindle 5, 10 r.p.m.
3. The emulsion concentrate of claim 1 wherein the emulsion is transparent.
4. The emulsion concentrate of claim 1 wherein the emulsion has a mean droplet size of less than 100 nm.
5. The emulsion concentrate of claim 4 wherein the mean droplet size is less than 50 nm.
6. The emulsion concentrate of claim 5 wherein the mean droplet size is less than 10 nm.
7. The emulsion concentrate of claim 1 wherein the C12-24 fatty alcohol is a cetyl alcohol, a stearyl alcohol or a combination thereof.
8. The emulsion concentrate of claim 1 wherein the hydrotrope is glycerol.
9. An emulsion concentrate comprising:
(a) 3 to 5% by weight lauryl glucoside,
(b) 1 to 2% by weight myristyl glucoside,
(c) 5 to 7% by weight polyglycerol-2-dipolyhydroxystearate,
(d) 4 to 8% by weight of stearyl alcohol or cetyl alcohol, or a combination thereof.
(e) 70 to 75% by weight of an oil component,
(f) 4 to 5% by weight of glycerol; and
(g) 2 to 10% by weight water.
10. A cosmetic or pharmaceutical composition comprising from 5 to 40% by weight of the emulsion concentrate of claim 1.
11. A cosmetic or pharmaceutical composition comprising from 5 to 40% by weight of the emulsion concentrate of claim 9.
12. A substrate for body care which is treated with the cosmetic or pharmaceutical composition of claim 10.
13. A substrate for body care which is treated with the cosmetic or pharmaceutical composition of claim 11.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for producing Plasmodium falciparum protein MSP-1 in milk of a non-human transgenic mammal, comprising:
1) providing a non-human transgenic mammal whose genome comprises a modified nucleic acid sequence encoding said MSP-1 operably linked to a promoter which directs expression in a mammary gland and a signal sequence directing secretion of said MSP-1 into milk, wherein said modified nucleic acid sequence has been modified by replacing a number of AT-containing codons of a nucleic acid sequence encoding said MSP-1, as it naturally occurs in Plasmodium falciparum, with a codon or codons preferred by a mammalian cell for the purpose of expression and encoding the same amino acid as the replaced AT-containing codon or codons, wherein the number of codons replaced is sufficient to allow expression of said MSP-1 in said non-human transgenic mammal; and
2) allowing said non-human transgenic mammal to express said MSP-1 in its milk.
2. A method for producing Plasmodium falciparum protein MSP-1 in milk of a non-human transgenic mammal, comprising:
1) providing a non-human transgenic mammal whose genome comprises a modified nucleic acid sequence encoding said MSP-1 operably linked to a promoter which directs expression in a mammary gland and a signal sequence directing secretion of said MSP-1 into milk, wherein said modified nucleic acid sequence has been modified by introduction of one or more silent mutations into a number of AUUUA mRNA instability motifs, as they naturally occur in Plasmodium falciparum, thereby eliminating said number of AUUUA instability motifs, allowing expression of said MSP-1 in said non-human transgenic mammal; and
2) allowing said non-human transgenic mammal to express said MSP-1 in its milk.
3. A method for producing Plasmodium falciparum protein MSP-1 in milk of a non-human transgenic mammal, comprising:
1) providing a non-human transgenic mammal whose genome comprises a modified nucleic acid sequence encoding said MSP-1 operably linked to a promoter which directs expression in a mammary gland and a signal sequence directing secretion of said MSP-1 into milk, wherein said modified nucleic acid sequence has been modified by:
a) replacing a number of AT-containing codons of a nucleic acid sequence encoding said MSP-1, as it naturally occurs in Plasmodium falciparum, with a codon or codons preferred by a mammalian cell for the purpose of expression and encoding the same amino acid as the replaced AT-containing codon or codons, and
b) introduction of one or more silent mutations into a number of AUUUA mRNA instability motifs, as they naturally occur in Plasmodium falciparum, thereby eliminating said AUUUA instability motifs,
wherein the number of said modifications is sufficient to allow expression of said MSP-1 in said non-human transgenic mammal; and
2) allowing said non-human transgenic mammal to express said MSP-1 in its milk.
4. The method of claim 1, 2 or 3 wherein the modified nucleic acid further comprises at least one substitution of a glutamine codon for an asparagine codon, resulting in the loss of at least one N-glycosylation site in said MSP-1.
5. A non-human transgenic mammal whose genome comprises a modified nucleic acid sequence encoding Plasmodium falciparum protein MSP-1 operably linked to a promoter which directs expression in a mammary gland and a signal sequence directing secretion of said MSP-1 into milk, wherein said modified nucleic acid sequence has been modified by replacing a number of AT-containing codons of a nucleic acid sequence encoding said MSP-1, as it naturally occurs in Plasmodium falciparum, with a codon or codons preferred by a mammalian cell for the purposes of expression and encoding the same amino acid as the replaced AT-containing codon or codons, wherein the number of codons replaced is sufficient to allow expression of said MSP-1 in said non-human transgenic mammal, and wherein said non-human transgenic mammal expresses said MSP-1 in its milk.
6. A non-human transgenic mammal whose genome comprises a modified nucleic acid sequence encoding Plasmodium falciparum protein MSP-1 operably linked to a promoter which directs expression in a mammary gland and a signal sequence directing secretion of said MSP-1 into milk, wherein said modified nucleic acid sequence has been modified by introduction of one or more silent mutations into a number of AUUUA mRNA instability motifs, as they naturally occur in Plasmodium falciparum, thereby eliminating said AUUUA instability motifs, allowing expression of said MSP-1 in said non-human transgenic mammal, and wherein said non-human transgenic mammal expresses said MSP-1 in its milk.
7. The non-human transgenic mammal of claim 6 wherein said modified nucleic acid sequence is further modified by introduction of one or more silent mutations into a number of AUUUA mRNA instability motifs, as they naturally occur in Plasmodium falciparum, thereby eliminating said AUUUA instability motifs, and allowing expression of said MSP-1.
8. The non-human transgenic mammal of claim 5, 6, or 7 wherein the modified nucleic acid further comprises at least one substitution of a glutamine codon for an asparagine codon, resulting in the loss of at least one N-glycosylation site in said MSP-1.